Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects

Nivasorexant, a selective orexin‐1‐receptor antagonist, has recently been assessed in the treatment of humans with binge‐eating disorder. Herein, the inhibitory potential of nivasorexant on cytochromes P450 (CYPs) 2C9, 2C19, and 3A4 was evaluated. Human liver microsomes/recombinant CYP enzymes were...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Benjamin, Kaufmann, Priska, Berse, Matthias, Treiber, Alexander, Grignaschi, Nathalie, Dingemanse, Jasper
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557102/
https://www.ncbi.nlm.nih.gov/pubmed/37800597
http://dx.doi.org/10.1002/prp2.1143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557102/
https://www.ncbi.nlm.nih.gov/pubmed/37800597
http://dx.doi.org/10.1002/prp2.1143

Ejemplares similares